Search

Reed M Benet

from Birmingham, MI
Age ~62

Reed Benet Phones & Addresses

  • 1801 Southfield Rd, Birmingham, MI 48009
  • 1935 Quarton Rd, Bloomfield Hills, MI 48301 (248) 792-6683
  • Bloomfield, MI
  • Davis, CA
  • 3 Acacia Ave, Belvedere Tiburon, CA 94920 (415) 435-1834
  • 53 Beach Rd, Belvedere Tiburon, CA 94920 (415) 435-3550
  • 12 Beach Rd, Belvedere Tiburon, CA 94920
  • 31 Acacia Ave, Belvedere, CA 94920 (415) 435-1834 (415) 435-9683
  • Somerville, MA

Resumes

Resumes

Reed Benet Photo 1

Founder And Chief Executive Officer

View page
Location:
271 Euclid Ave, Birmingham, MI 48009
Industry:
Financial Services
Work:
Wells Fargo Advisors 2013 - 2014
Financial Advisor

Herohomes.com 2013 - 2014
Founder and Chief Executive Officer

Morgan Stanley 2011 - 2013
Financial Advisor

Booz Allen Hamilton 2009 - 2011
Strategy and Technology Consultant

University of Texas Austin Cleantech Incubator 2008 - 2008
Managing Director
Education:
University of California, Davis 2004 - 2008
Doctorates, Doctor of Philosophy, Engineering
Harvard Business School 1989 - 1991
Master of Business Administration, Masters, Entrepreneurship
Princeton University 1980 - 1984
Bachelors, Bachelor of Arts, Politics
University of California
Interests:
Family
Endurance Athletics
Business History
Languages:
English
German
Reed Benet Photo 2

Financial Advisor -- Global Wealth Management

View page
Location:
Birmingham, MI
Industry:
Financial Services
Work:
Morgan Stanley
Financial Advisor -- Global Wealth Management

Business Records

Name / Title
Company / Classification
Phones & Addresses
Reed Benet
Principal
Valorvillages
Subdivider/Developer
1935 Quarton Rd, Bloomfield, MI 48301

Publications

Us Patents

Use Of Essential Oils To Increase Bioavailability Of Oral Pharmaceutical Compounds

View page
US Patent:
57169284, Feb 10, 1998
Filed:
Jun 7, 1995
Appl. No.:
8/478207
Inventors:
Leslie Z. Benet - Belvedere CA
Vincent J. Wacher - San Francisco CA
Reed M. Benet - Belvedere CA
Assignee:
AvMax, Inc. - Berkeley CA
International Classification:
A61K 3112
US Classification:
514 11
Abstract:
A method for increasing bioavailability and reducing inter- and intra-individual variability of an orally administered hydrophobic pharmaceutical compound, which comprises orally administering the pharmaceutical compound to a mammal in need of treatment with the compound concurrently with an essential oil or essential oil component in an amount sufficient to provide bioavailability of the compound in the presence of the essential oil or essential oil component greater than bioavailability of the compound in the absence of the essential oil or essential oil component, wherein the essential oil or essential oil component has an activity of at least 10% inhibition at a concentration of 0. 01 wt. % or less in an assay that measures conversion of cyclosporine to hydroxylated products using an assay system containing 250/. mu. g rat liver microsomes, 1. mu.

Use Of Benzoin Gum To Inhibit P-Glycoprotein-Mediated Resistance Of Pharmaceutical Compounds

View page
US Patent:
59165669, Jun 29, 1999
Filed:
Feb 11, 1998
Appl. No.:
8/973593
Inventors:
Leslie Z. Benet - Belvedere CA
Vincent J. Wacher - San Francisco CA
Reed M. Benet - Belvedere CA
Assignee:
AvMax, Inc. - Berkeley CA
International Classification:
A61K 3578
A61K 31335
US Classification:
4241951
Abstract:
A method for increasing bioavailabilty of an orally administered hydrophobic pharmaceutical compound, which comprises orally administering the pharmaceutical compound to a mammal in need of treatment with the compound concurrently with an essential oil or essential oil component in an amount sufficient to provide bioavailability of the compound in the presence of the essential oil or essential oil component greater than bioavailability of the compound in the absence of the essential oil or essential oil component, wherein the essential oil or essential oil component has an activity of at least 10% inhibition at a concentration 0. 01 wt. % or less in an assay that measures reduced conversion of cyclosporine to hydroxylated products using an assay system containing 250. mu. g rat liver microsomes, 1. mu. M cyclosporine, and 1. mu.

Use Of Essential Oils To Increase Bioavailability Of Orally Administered Pharmaceutical Compounds

View page
US Patent:
61212342, Sep 19, 2000
Filed:
Feb 6, 1998
Appl. No.:
9/019936
Inventors:
Leslie Z. Benet - Belvedere CA
Vincent J. Wacher - San Francisco CA
Reed M. Benet - Belvedere CA
Assignee:
AvMax, Inc. - Berkeley CA
International Classification:
A61K 3112
US Classification:
514 11
Abstract:
A method for increasing bioavailability and reducing inter- and intra-individual variability of an orally administered hydrophobic pharmaceutical compound, which comprises orally coadministering the pharmaceutical compound to a mammal in need of treatment with the compound with an essential oil or essential oil component in an amount sufficient to provide bioavailability of the compound in the presence of the essential oil or essential oil component greater than bioavailability of the compound in the absence of the essential oil or essential oil component, wherein the essential oil or essential oil component has an activity of at least 10% inhibition at a concentration of 0. 01 wt. % or less in an assay that measures conversion of cyclosporine to hydroxylated products using an assay system containing 250. mu. g rat liver microsomes, 1. mu.

Use Of Essential Oils To Increase Bioavailability Of Oral Pharmaceutical Compounds

View page
US Patent:
56653867, Sep 9, 1997
Filed:
Jun 7, 1995
Appl. No.:
8/486186
Inventors:
Leslie Z. Benet - Belvedere CA
Vincent J. Wacher - San Francisco CA
Reed M. Benet - Belvedere CA
Assignee:
AvMax, Inc. - Berkeley CA
International Classification:
A61K 948
US Classification:
424451
Abstract:
A method for increasing bioavailability and reducing inter- and intra-individual variability of an orally administered hydrophobic pharmaceutical compound, which comprises orally administering the pharmaceutical compound to a mammal in need of treatment with the compound concurrently with an essential oil or essential oil component in an amount sufficient to provide bioavailability of the compound in the presence of the essential oil or essential oil component greater than bioavailability of the compound in the absence of the essential oil or essential oil component, wherein the essential oil or essential oil component has an activity of at least 10% inhibition at a concentration of 0. 01 wt. % or less in an assay that measures conversion of cyclosporine to hydroxylated products using an assay system containing 250. mu. g rat liver microsomes, 1. mu.
Reed M Benet from Birmingham, MI, age ~62 Get Report